Strategic report Governance & remuneration Financial statements Investor information 44 Principal Group companies The following represent the principal subsidiaries and their countries of incorporation of the Group at 31 December 2015.
The equity share capital of these entities is wholly owned by the Group except where its percentage interest is shown otherwise.
All companies are incorporated in their principal country of operation except where stated.
England US Glaxo Group Limited Block Drug Company, Inc. Glaxo Operations UK Limited Corixa Corporation GlaxoSmithKline Capital plc GlaxoSmithKline Capital Inc. GlaxoSmithKline Consumer Healthcare Holdings Limited 63.5% GlaxoSmithKline Consumer Healthcare, L. P. 55.9% GlaxoSmithKline Consumer Healthcare UK Trading Limited 63.5% GlaxoSmithKline Holdings Americas Inc. GlaxoSmithKline Export Limited GlaxoSmithKline LLC GlaxoSmithKline Finance plc Human Genome Sciences, Inc. GlaxoSmithKline Holdings Limited Novartis Consumer Health, Inc. GlaxoSmithKline Research & Development Limited Stiefel Laboratories, Inc. GlaxoSmithKline Services Unlimited ViiV Healthcare Company 78.3% GlaxoSmithKline UK Limited Setrst Limited SmithKline Beecham Limited ViiV Healthcare Limited 78.3% ViiV Healthcare UK Limited 78.3% Europe Others GlaxoSmithKline Biologicals S. A. Belgium GlaxoSmithKline Argentina S. A. Argentina GlaxoSmithKline Pharmaceuticals S. A. Belgium GlaxoSmithKline Australia Pty Ltd. Australia GlaxoSmithKline Biologicals S. A. S. France GlaxoSmithKline Brasil Limitada Brazil Groupe GlaxoSmithKline S. A. S. France GlaxoSmithKline Inc. Canada Laboratoire GlaxoSmithKline S. A. S. France ID Biomedical Corporation of Quebec Canada ViiV Healthcare S. A. S. France 78.3% GlaxoSmithKline China Investment Co. Ltd. China GlaxoSmithKline Consumer Healthcare GmbH & Co. KG GlaxoSmithKline Limited China Germany 63.5% GlaxoSmithKline Pharmaceuticals Suzhou Limited China GlaxoSmithKline GmbH & Co. KG Germany Sino-American Tianjin Smith Kline & French Laboratories Ltd. China 34.9% Novartis Consumer Health GmbH Germany 63.5% GlaxoSmithKline Consumer Healthcare Limited India 72.5% GlaxoSmithKline Consumer Healthcare S. p. A. Italy 63.5% GlaxoSmithKline Pharmaceuticals Limited India 75% GlaxoSmithKline S. p. A. Italy GlaxoSmithKline Consumer Healthcare Japan K. K. Japan GlaxoSmithKline B. V. Netherlands GlaxoSmithKline K. K. Japan GlaxoSmithKline Pharmaceuticals S. A. Poland GlaxoSmithKline Mexico S. A. fide C. V. Mexico GSK Services Sp.
z. o. o. Poland GlaxoSmithKline Pakistan Limited Pakistan 82.6% GlaxoSmithKline Trading Services Limited Republic of Ireland i Glaxo Wellcome Manufacturing Pte Ltd. Singapore GlaxoSmithKline S. A. Spain GlaxoSmithKline Pte Ltd. Singapore Novartis Consumer Health S. A. Switzerland 63.5% GlaxoSmithKline Korea Limited South Korea GlaxoSmithKline llaclari Sanayi five Ticaret A. S. Turkey i Exempt from the provisions of section 347 and 348 of the Companies Act 2014 Ireland, in accordance with the exemptions noted in Section 357 of that Act.
Further subsidiaries, as disclosed on pages 250 to 258, are exempt from these provisions as they are also consolidated in the group financial statements.
Directly held wholly owned subsidiary of GlaxoSmithKline plc.
The subsidiaries and associates listed above principally affect the gures in the Groups financial statements.
Each of GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc is a wholly-owned finance subsidiary of the company, and the company has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc.
See pages 250 to 258 for a complete list of subsidiary undertakings, associates and joint ventures, which form part of these financial statements.
